References
1. Pfeilschifter J, Pignat W, Vosbeck K, Marki F. Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase release from rat renal mesangial cells. Biochem Biophys Res Comm. 1989; 159(2):385-94.
2. Ross R. Atherosclerosis-an inflammatory disease. N Eng J Med 1999;340(2):115-26.
3. Blake GJ and Ridker PM. Novel clnical markers of vascular wall inflammation Cir Res 2001;89(9):763-71.
4. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105(9):1135-43.
5. Webb NR. Secretory phospholipase enzymes in atherogenesis. Curr Opin Lipidol 2005; 16(3):341-44.
6. Harford M, Wiklund O, Mattsson-Hulten L, Perers E, Person A, Herlitz J, et. Al. CRP, interleukin-6, secretory phospholipase group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol 2006;108(1):55-62.
7. Ivandic B, Castellani LW, Wang X-P, Qiao J-H, Mehrabian M, Navab M, Fogelman A, Grass D, Swanson M, de Beer MC, de Beer F, Lusis AJ. Role of Group II secretory phospholipase A2 in atherosclerosis 1, Increased atherogenesis and altered lipoproteins in transgenic mice expressing Group IIA phospholipase A2. Arteriosclerosis Thrombosis and Vascular Biology1999;19:1284–90
8. Rosengren B, Peilot H, Umaerus M, Jönsson-Rylander A-C, Mattsson-Hultén L, Hallberg C, Cronet P, Rodriguez-Lee M, Hurt-Camejo E. Secretory Phospholipase A2 Group V: Lesion Activation by Arterial Proteoglycans, and Induction in Aorta by a Western Diet. Arteriosclerosis Thrombosis and Vascular Biology 2006;26:1579-1585
9. Bostrom MA, Boyanovsky BB, Jordan CT, Wadsworth MP, Taatjes DJ, de Beer FC, Webb NR). Group V Secretory Phospholipase A2 Promotes Atherosclerosis. Evidence from genetically altered mice. Arteriosclerosis Thrombosis and Vascular Biology 2007
10. de Beer FC, Connell P, Yu J, de Beer MC, Webb NR, van der Westhuyzen DR. HDL modification by secretory phospholipase A2 promotes scavenger receptor class B type I interaction and accelerates HDL catabolism Journal of Lipid Research2000;41:1849–57
11. Sartipy P, Camejo G, Svensson L, Hurt-Camejo E. Phospholipase A2 modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans Journal of Biological Chemistry 1999;274 (36):25913–20
12. Sparrow CP, Parthasarathy S, Steinberg D. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification Journal of Lipid Research 1988;29:745-753
13. Hanasaki K, Yamada K, Yamamoto S, Ishimoto Y, Saiga A, Ono T, Ikeda M, Notoya M, Kamitani S, Arita H. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation Journal of Biological Chemistry 2002 277(32):29116–24
14. Hurt-Camejo E, Camejo G, Peilot H, Őörni K, Kovanen PT. Phospholipase A2 in vascular disease, Circulation Research 2001;89:298-304
15. Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, Sakamoto T, Soejima H, Ogawa H, Doi H, Sugiyama S, Yasue H . Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease Circulation 1999;100(12):1280–84
16. Fichlscherer S, Kaszkin M, Breuer S, Dimmeler S, Zeiher AM. Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease Clinical Science 2004;106:511-517
17. Liu PY, Li YH, Tsai WC, Chao TH, Tsai LM, Wu HL, Chen JH. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention European Heart Journal 2003;24(2):1824–32
18. Korotaeva AA, Samoilova EV, Kaminny AI, Pirkova AA, Resink TJ, Erne P, Prokazova N, Tkachuk V, Chazov E. The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL Molecularand Cellular Biochemistry 2005;270(1-2):107–13
19. Hartford M, Wiklund O, Mattsson-Hulten L, Perers E, Person A, Herlitz J, et. al. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up International Journal of Cardiology2006;108(1):55–62
20. Arakawa N, Endo S, Nakamura M, Saito S, Inada K, Ogawa M, Hiramori K. Increased Plasma Group II Phospholipase A2 Concentrations in Patients with Acute Myocardial Infarction: Correlation with Tumour Necrosis Factor-Alpha Cardiology 2000;94:106-110
21. Nijmeijer R, Lagrand WK, Baidoshvili A, Lubbers YT, Hermens WT, Meijer CJ, et. al. Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans (CardiovascularResearch2002;53(1):138–46
22. Ishikawa Y, Komiyama K, Masuda S, Murakami M, Akasaka Y, Ito K, Akishima-Fukasawa Y, Kimura M, Fujimoto A, Kudo I, Ishii T. Expression of type V phospholipase A2 in myocardial remodeling after infarction Histopathology 2005:47:257-267
23. Kugiyama K, Ota Y, Sugiyama S, Kawano H, Doi H, Soejima H, Miyamoto S, Ogawa H, Takazoe K, Yasue H. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris American Journal of Cardiology 2000;86(7):718–22
24Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, Daboous Oh, Henry P, Carruthers KF, Dauphin A, Arguelles CS, Masliah J, Hugel B, Montalescot G, Freyssinet JM, Asselain B, Tedgui A. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. Journal of the American College of Cardiology 2005;46(7):1249–57
25. Porela P, Pulkki K, Voipio-Pulkki LM, Pettersson K, Leppanen V, Nevalainen TJ). Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction Basic Research in Cardiology 2000;95(5):413–17
26. Zalewski A, Goldberg S, Maroko PR. The effects of phospholipase A2 inhibition on experimental infarct size, left ventricular hemodynamics and regional myocardial blood flow International Journal of Cardiology 1988;21(3):247-257
27. Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, Sandhu MS, Jukema JW, Kastelein JJP Hack CE, Khaw KT. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study Arteriosclerosis Thrombosis and VascularBiology 2005;25(4):839–46
28. Mallat Z, Simon T, Benessiano J, Ederhy S, Sebella-Arguelles C, Cohen A, Huart V, Wareham N, Luben R, Khaw k-T, Tedgui A, Boekholdt M. Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women The EPIC_NORFOLK Study Arteriosclerosis Thrombosis and Vascular Biology 2007;27
29. Johnson‚ C.S. The acute chest syndrome. Hematol Oncol Clin N Am 2005;19:857–79.
30. Castro‚ O.‚ Brambilla‚ D.J.‚ Thorington‚ B.‚ et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. Blood 1994:84(2):643–9.
31. Prakash‚ U.B.S. Lungs in hemoglobinopathies‚ erythrocyte disorders‚ and hemorrhagic diatheses. Semin Respir Crit Care Med 2005;26(5):527–40
32. Facts About Sickle Cell. Bethesda‚ MD: U.S. Department of Health & Human Services‚ National Institutes of Health‚ National Heart‚ Lung‚ and Blood Institute; November 1996. NIH Publication #:96–4057.
33. Okpala‚ I.E. New therapies for sickle cell disease. Hematol Oncol Clin N Am 2005:19:975–87.
34. Styles‚ LA‚ Schalkwijk‚ CG‚ Aarsman‚ AJ‚ et al. Phospholipase levels in acute chest syndrome of sickle cell disease. Blood 1996:87(6):2573–78.
35. Styles‚ LA‚ Aarsman‚ AJ‚ Vichinsky‚ EP‚ et al. Secretory phospholipase predicts impending acute chest syndrome in sickle cell disease. Blood 2000;96(9):3276–78.
36. Naprawa‚ JT‚ Bonsu‚ BK‚ Goodman‚ DG‚ et al. Serum biomarkers for identifying acute chest syndrome among patients who have sickle cell disease and present to the emergency department. Pediatrics 2005:116:e420–e425.
37. Styles‚ LA‚ Abboud‚ M‚ Larkin‚ S. et al. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase. Submitted.
38. LUPUS FOUNDATION OF AMERICA. Retrieved on 2008-02-06.
39. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Parks CG, and Gilkeson GS. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum. 1998;41(10):1714–24.
40. Browning JL. B Cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov. 2006;5(7):564–76.
41. Edwards JC and Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol. 2006;6(5):394–403.
42. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol. 2001;2(9):764–66.
43. Chan OT, Hannum LG, Haberman AM, Madaio MP, and Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999;189(10):1639–48
44. Wiesendanger M, Stanevsky A, Kovsky S, and Diamond B. Novel therapeutics for systemic lupus erythematosus. Curr Opin Rheumatol. 2006;18(3):227–35.
45. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, et. al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci. 2005;1050:34–39.
46. Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166(1):6–10.
47. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome J Clin Invest. 2002;109(1):59–68.
48. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, and Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun. 2002;3(7):424–29.
49. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, Solovyev I, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci 2000;97(7):3370–75.
50. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190(11):1697–710.